FIGURE 2.

A, diagram of overlapping response elements within the Fgf21 promoter region. The boxed (dashed line) region of the promoter was utilized for EMSA. B, formation of the ChREBP-MLX complex with a control labeled oligonucleotide (lanes 1–4) and at the Fgf21 ChoRE (lanes 5–8). C, TCDD induces AHR-ARNT heterodimerization and binding to a control ³²P-labeled oligonucleotide. D, TCDD and ICZ treatment results in formation of the AHR-ARNT complex at the Fgf21 DRE. E, addition of unlabeled oligonucleotide interrupts AHR-ARNT binding to the Fgf21 DRE (lanes 1 and 2). Introducing a mutation into the DRE of the unlabeled oligonucleotide eliminates this competitive binding (lanes 3 and 4). All data are representative of at least two independent experiments.